Please assess the completion status of the following clinical trial:

Trial Title: Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histological diagnosis of CD20+ B cell lymphoma subtypes: marginal zone lymphoma, grade 1-2 follicular lymphoma, plasmocytic lymphoma, small lymphocyte lymphoma~* conjunctival localization alone (1EA stage; mono- or bilateral)~* at least one measurable lesion~* age \>/= 18 years~* ECOG-PS \</=3~* HIV 1-2 negativity~* at least one previous treatment (antibiotic or rituximab)~Exclusion Criteria:~* concomitant conventional (chemo-, radiation, immuno-), experimental (antibiotic) or corticosteroid anticancer therapy~* known allergy to rituximab~* systemic symptoms~* concurrent diagnosis of pemphigus~* postsurgical conjunctival scars

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intralesional rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).